Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

NCT06580314 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT06580314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06580314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
March 12, 2025
Completion date
December 31, 2034
Enrollment
880 (estimated)
Sites
695

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube endometrioid adenocarcinoma, fallopian tube high grade serous adenocarcinoma, fallopian tube malignant mixed mesodermal (mullerian) tumor, figo stage iii ovarian cancer 2014, figo stage iv ovarian cancer 2014, ovarian carcinoma, ovarian carcinosarcoma, ovarian high grade endometrioid adenocarcinoma, ovarian high grade serous adenocarcinoma, primary peritoneal carcinosarcoma, primary peritoneal endometrioid adenocarcinoma, primary peritoneal high grade serous adenocarcinoma